Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Packer

Showing results (661-670 of 706) with videos related to

Pageof 71
Sort By:
Scientific Reports|July 4, 2020
Harmonization of postmortem donations for pediatric brain tumors and molecular characterization of diffuse midline gliomasMadhuri Kambhampati, Eshini Panditharatna, Sridevi Yadavilli, et al.
Journal of Medicinal Chemistry|September 28, 2024
Optimization of Potent, Efficacious, Selective and Blood-Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion MutationsClare Thomson, Erin Braybrooke, Nicola Colclough, et al.
Neuro-Oncology|October 11, 2017
Pediatric low-grade gliomas: next biologically driven stepsDavid T W Jones, Mark W Kieran, Eric Bouffet, et al.
Journal of Medicinal Chemistry|January 30, 2026
Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate CancerJames S Scott, Laura Evans, Peter C Astles, et al.
Neuro-Oncology|September 30, 2016
Pediatric low-grade gliomas: implications of the biologic eraRoger J Packer, Stephan Pfister, Eric Bouffet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2021
Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk MedulloblastomaJeff M Michalski, Anna J Janss, L Gilbert Vezina, et al.
Bioorganic & Medicinal Chemistry Letters|May 22, 2012
Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetesWilliam McCoull, Matthew S Addie, Alan M Birch, et al.
Neurology|December 14, 2016
Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1Jonathan M Payne, Belinda Barton, Nicole J Ullrich, et al.
Nature Medicine|January 14, 2021
Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trialMichael J Fisher, Chie-Schin Shih, Steven D Rhodes, et al.
The Lancet. Oncology|June 2, 2019
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trialJason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Pageof 71

Showing results (661-670 of 706) with videos related to

Sort By:
Pageof 71
Scientific Reports|July 4, 2020
Harmonization of postmortem donations for pediatric brain tumors and molecular characterization of diffuse midline gliomasMadhuri Kambhampati, Eshini Panditharatna, Sridevi Yadavilli, et al.
Journal of Medicinal Chemistry|September 28, 2024
Optimization of Potent, Efficacious, Selective and Blood-Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion MutationsClare Thomson, Erin Braybrooke, Nicola Colclough, et al.
Neuro-Oncology|October 11, 2017
Pediatric low-grade gliomas: next biologically driven stepsDavid T W Jones, Mark W Kieran, Eric Bouffet, et al.
Journal of Medicinal Chemistry|January 30, 2026
Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate CancerJames S Scott, Laura Evans, Peter C Astles, et al.
Neuro-Oncology|September 30, 2016
Pediatric low-grade gliomas: implications of the biologic eraRoger J Packer, Stephan Pfister, Eric Bouffet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2021
Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk MedulloblastomaJeff M Michalski, Anna J Janss, L Gilbert Vezina, et al.
Bioorganic & Medicinal Chemistry Letters|May 22, 2012
Identification, optimisation and in vivo evaluation of oxadiazole DGAT-1 inhibitors for the treatment of obesity and diabetesWilliam McCoull, Matthew S Addie, Alan M Birch, et al.
Neurology|December 14, 2016
Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1Jonathan M Payne, Belinda Barton, Nicole J Ullrich, et al.
Nature Medicine|January 14, 2021
Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trialMichael J Fisher, Chie-Schin Shih, Steven D Rhodes, et al.
The Lancet. Oncology|June 2, 2019
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trialJason Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, et al.
Pageof 71